eltrombopag combining rituximab

ApprovedMonoclonal antibody

IInstitute of Hematology & Blood Diseases Hospital, China

eltrombopag combining rituximab is one of 41 small molecule programs targeting Immune Thrombocytopenia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune ThrombocytopeniaActive, not recruiting

Immune ThrombocytopeniaApproved

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Nplate

Amgen

Phase 3

8 2

Rysodeg

UCB

Phase 3

3 3

Cellcept

Roche

Phase 3

2 4

Doptelet

AAkarx

Phase 3

6 5

Vyvgart

Argenx

Phase 3

6 6

Fabhalta

Johnson & Johnson

Phase 3

—7

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

3 8

Wayrilz

GGenzyme, a Sanofi Company

Phase 3

3 9

Avlosulfon

AAlmirall, S.A.

Phase 3

1 10

Tamiflu

CConrado Roberto Hoffmann Filho

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immune Thrombocytopenia1 trial

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 4·NCT04518475·224 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for eltrombopag combining rituximab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — eltrombopag combining rituximab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for eltrombopag combining rituximab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Approved[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

eltrombopag combining rituximab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immune Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News